None
Quote | H/Cell Energy Corp (OTCMKTS:HCCC)
Last: | $0.15 |
---|---|
Change Percent: | -40.0% |
Open: | $0.25 |
Close: | $0.15 |
High: | $0.25 |
Low: | $0.15 |
Volume: | 6,667 |
Last Trade Date Time: | 10/05/2020 04:44:07 am |
News | H/Cell Energy Corp (OTCMKTS:HCCC)
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview ...
- Positive interim safety and feasibility data from pancreatic cancer study in Montreal , with initial signs of potential dose response findings - - ReSTART U.S. multi-center pivotal trial currently underway - - Submitted PMDA appl...
Message Board Posts | H/Cell Energy Corp (OTCMKTS:HCCC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
H/Cell Energy Corp Company Name:
HCCC Stock Symbol:
OTCMKTS Market:
JERUSALEM, March 25, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that CFO Raphi Levy will present a corporate overview ...
- Positive interim safety and feasibility data from pancreatic cancer study in Montreal , with initial signs of potential dose response findings - - ReSTART U.S. multi-center pivotal trial currently underway - - Submitted PMDA appl...
JERUSALEM, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate at the Barclays 26 th An...